BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38496268)

  • 41. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemokine saliva levels in patients with primary Sjögren's syndrome, associated Sjögren's syndrome, pre-clinical Sjögren's syndrome and systemic autoimmune diseases.
    Hernández-Molina G; Michel-Peregrina M; Hernández-Ramírez DF; Sánchez-Guerrero J; Llorente L
    Rheumatology (Oxford); 2011 Jul; 50(7):1288-92. PubMed ID: 21330342
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overlap of ACA-positive systemic sclerosis and Sjögren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma.
    Baldini C; Mosca M; Della Rossa A; Pepe P; Notarstefano C; Ferro F; Luciano N; Talarico R; Tani C; Tavoni AG; Bombardieri S
    Clin Exp Rheumatol; 2013; 31(2):272-80. PubMed ID: 23343785
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An Overview of the Dry Eye Disease in Sjögren's Syndrome Using Our Current Molecular Understanding.
    Wu KY; Kulbay M; Tanasescu C; Jiao B; Nguyen BH; Tran SD
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675090
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Natural History and Predictors of Progression to Sjögren's Syndrome Among Participants of the Sjögren's International Collaborative Clinical Alliance Registry.
    Shiboski CH; Baer AN; Shiboski SC; Lam M; Challacombe S; Lanfranchi HE; Schiødt M; Shirlaw P; Srinivasan M; Umehara H; Vivino FB; Akpek E; Bunya V; Vollenweider CF; Greenspan JS; Daniels TE; Criswell LA;
    Arthritis Care Res (Hoboken); 2018 Feb; 70(2):284-294. PubMed ID: 28437595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren's syndrome versus non-Sjogren's syndrome.
    Cubuk MO; Ucgul AY; Ozgur A; Ozulken K; Yuksel E
    Int Ophthalmol; 2021 Apr; 41(4):1479-1485. PubMed ID: 33484384
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study).
    van Nimwegen JF; Mossel E; van Zuiden GS; Wijnsma RF; Delli K; Stel AJ; van der Vegt B; Haacke EA; Olie L; Los LI; Verstappen GM; Pringle SA; Spijkervet FKL; Kroese FGM; Vissink A; Arends S; Bootsma H
    Lancet Rheumatol; 2020 Mar; 2(3):e153-e163. PubMed ID: 38263653
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Childhood-onset primary Sjögren's syndrome in a tertiary center in China: clinical features and outcome.
    Gong Y; Liu H; Li G; Zhang T; Li Y; Guan W; Zeng Q; Lv Q; Zhang X; Yao W; Shi Y; Xu H; Sun L
    Pediatr Rheumatol Online J; 2023 Jan; 21(1):11. PubMed ID: 36707855
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements.
    Ramos-Casals M; Brito-Zerón P; Seror R; Bootsma H; Bowman SJ; Dörner T; Gottenberg JE; Mariette X; Theander E; Bombardieri S; De Vita S; Mandl T; Ng WF; Kruize A; Tzioufas A; Vitali C;
    Rheumatology (Oxford); 2015 Dec; 54(12):2230-8. PubMed ID: 26231345
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study.
    de Frémont GM; Costedoat-Chalumeau N; Lazaro E; Belkhir R; Guettrot-Imbert G; Morel N; Nocturne G; Molto A; Goulenok T; Diot E; Perard L; Ferreira-Maldent N; Le Besnerais M; Limal N; Martis N; Abisror N; Debouverie O; Richez C; Sobanski V; Maurier F; Sauvetre G; Levesque H; Timsit MA; Tieulié N; Orquevaux P; Bienvenu B; Mahevas M; Papo T; Lartigau-Roussin C; Chauvet E; Berthoux E; Sarrot-Reynauld F; Raffray L; Couderc M; Silva NM; Jourde-Chiche N; Belhomme N; Thomas T; Poindron V; Queyrel-Moranne V; Delforge J; Le Ray C; Pannier E; Mariette X; Le Guern V; Seror R;
    Lancet Rheumatol; 2023 Jun; 5(6):e330-e340. PubMed ID: 38251600
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
    Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren's syndrome: evidence- and practice-based guidance.
    Marinho A; Delgado Alves J; Fortuna J; Faria R; Almeida I; Alves G; Araújo Correia J; Campar A; Brandão M; Crespo J; Marado D; Matos-Costa J; Oliveira S; Salvador F; Santos L; Silva F; Fernandes M; Vasconcelos C
    Front Immunol; 2023; 14():1117699. PubMed ID: 37138867
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Beyond dry eye: The greater extent of Sjögren's systemic disease symptoms, the impact of COVID-19 and perceptions towards telemedicine identified through a patient co-designed study.
    Greenan E; Tynan G; Collins D; Murphy CC; Flood M; Ní Gabhann-Dromgoole J
    Health Expect; 2023 Dec; 26(6):2252-2263. PubMed ID: 37470291
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical manifestations and immunological features of primary Sjögren's syndrome with liver involvement: analysis of thirty cases.
    Zhang Z; Dong Y
    Chin Med J (Engl); 1998 Mar; 111(3):220-3. PubMed ID: 10374420
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic performance of serology against histologic assessment to diagnose Sjogren's syndrome: a systematic review.
    Viegas-Costa LC; Friesen R; Flores-Mir C; McGaw T
    Clin Rheumatol; 2021 Dec; 40(12):4817-4828. PubMed ID: 34142295
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Contemporary diagnostics of the primary Sjögren's syndrome].
    Parada-Turska J
    Wiad Lek; 2016; 69(4):680-685. PubMed ID: 27941210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Unexplained cough: it is time to rule out Sjogren's syndrome.
    Koslow M; Kivity S; Vishnevskia-Dai V; Ben-Dov I
    Clin Rheumatol; 2018 May; 37(5):1215-1222. PubMed ID: 29388084
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association between systemic activity ındex and dry eye severity in patients with primary Sjögren syndrome.
    Ozek D; Kemer OE; Omma A
    Arq Bras Oftalmol; 2019; 82(1):45-50. PubMed ID: 30403265
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Parotid elastography: a potential alternative to replace labial biopsy in classification of patients with primary Sjögren's syndrome?
    Satış H; Cindil E; Salman RB; Yapar D; Demir NB; Temel E; Babaoğlu H; Ataş N; Karadeniz H; Avanoğlu Güler A; Oktar S; Tufan A; Öztürk MA; Haznedaroğlu Ş; Göker B
    Clin Rheumatol; 2020 Dec; 39(12):3707-3713. PubMed ID: 32458244
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.